Liberum Capital Reiterates GBX 2825.00 Price Target On Victrex PLC (LON:VCT), Reiterates Buy Rating; 7 Analysts Are Bullish The Royal Bank of Scotland Group plc (RBS) Last Week

Among 21 analysts covering Royal Bank of Scotland Group plc (ADR) (NYSE:RBS), 7 have Buy rating, 1 Sell and 13 Hold. Therefore 33% are positive. Royal Bank of Scotland Group plc (ADR) had 38 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of The Royal Bank of Scotland Group plc (NYSE:RBS) has “Hold” rating given on Wednesday, September 2 by Societe Generale. The company was downgraded on Monday, June 27 by RBC Capital Markets. The stock of The Royal Bank of Scotland Group plc (NYSE:RBS) has “Hold” rating given on Friday, August 11 by HSBC. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, August 26. The stock of The Royal Bank of Scotland Group plc (NYSE:RBS) earned “Neutral” rating by Goldman Sachs on Tuesday, January 17. Investec maintained the shares of RBS in report on Tuesday, August 4 with “Buy” rating. The rating was downgraded by Bernstein on Tuesday, January 2 to “Mkt Perform”. The company was upgraded on Tuesday, February 21 by Barclays Capital. The company was downgraded on Monday, June 27 by Jefferies. Citigroup upgraded The Royal Bank of Scotland Group plc (NYSE:RBS) on Tuesday, October 10 to “Hold” rating. See The Royal Bank of Scotland Group plc (NYSE:RBS) latest ratings:

02/01/2018 Broker: Bernstein Old Rating: Outperform New Rating: Mkt Perform Downgrade
10/10/2017 Broker: Citigroup Rating: Hold Upgrade
10/10/2017 Broker: Credit Suisse Rating: Hold Upgrade
05/10/2017 Broker: BNP Paribas Old Rating: Neutral New Rating: Outperform Upgrade
27/09/2017 Broker: Jefferies Old Rating: Hold New Rating: Buy Upgrade
22/09/2017 Broker: Bank of America Old Rating: Underperform New Rating: Neutral Upgrade
04/09/2017 Broker: RBC Capital Markets Rating: Hold Upgrade
11/08/2017 Broker: HSBC Old Rating: Reduce New Rating: Hold Upgrade

In analysts report issued on today, Liberum Capital kept their Buy rating on Victrex PLC (LON:VCT)‘s stock. The price target would suggest a potential upside of 16.88% from company’s current price.

The stock increased 0.50% or GBX 12 during the last trading session, reaching GBX 2424. About 125,679 shares traded. Victrex plc (LON:VCT) has 0.00% since February 9, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 16 analysts covering Victrex PLC (LON:VCT), 4 have Buy rating, 1 Sell and 11 Hold. Therefore 25% are positive. Victrex PLC has GBX 2825 highest and GBX 1400 lowest target. GBX 2159.56’s average target is -10.91% below currents GBX 2424 stock price. Victrex PLC had 155 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Victrex plc (LON:VCT) has “Hold” rating given on Thursday, September 28 by Deutsche Bank. As per Monday, February 6, the company rating was downgraded by Peel Hunt. As per Friday, February 5, the company rating was upgraded by N+1 Singer. On Tuesday, August 23 the stock rating was maintained by Credit Suisse with “Outperform”. The firm has “Neutral” rating by UBS given on Monday, August 21. UBS maintained the shares of VCT in report on Thursday, October 8 with “Neutral” rating. The stock has “Hold” rating by Deutsche Bank on Wednesday, September 28. The firm has “Buy” rating given on Monday, February 1 by Liberum Capital. The firm has “Neutral” rating by JP Morgan given on Tuesday, September 5. Deutsche Bank maintained Victrex plc (LON:VCT) rating on Wednesday, July 27. Deutsche Bank has “Hold” rating and GBX 1600 target.

Victrex plc, through its subsidiaries, makes and sells polymers worldwide. The company has market cap of 2.08 billion GBP. It operates through two divisions, Victrex Polymer Solutions and Invibio Biomaterial Solutions. It has a 20.9 P/E ratio. The firm offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.